ArticleJournal of gynecologic oncology2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study.
Article in Journal of gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.Cancer medicine · 2026Pooled it
- Prevalence and Factors Associated With Financial Toxicity in Cervical Cancer Patients: A Cross-Sectional Study.Nursing open · 2026Article
- Baseline Financial Toxicity and Cost-Coping Mechanisms Among Patients Presenting for Radiation Therapy.Advances in radiation oncology · 2026Article
- Financial Toxicity in Patients With Breast Cancer Treated at Private Medicine Institutions in Brazil.Cancer medicine · 2026Article
- Article
- Assessing long-term quality of life and survivorship priorities in cervical cancer patients: a social media survey-based study.Gynecologic oncology reports · 2026Article
- Article
- Social Needs in Cancer Survivors: A Scoping Review and Future Directions.Current oncology reports · 2025Article
- Non-monetary burdens of out-of-pocket costs incurred by patients and caregivers for medical care: a scoping review.BMJ open · 2025Article
- Financial toxicity, coping strategies, and quality of life among Chinese patients with hematologic malignancies: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Observational
- Socioeconomic disparities in risk of financial toxicity following elective cardiac operations in the United States.PloS one · 2024Article
- Identifying the factors affecting financial toxicity status in patients with middle and advanced colorectal cancer: a cross-sectional study.Frontiers in public health · 2024Article
- Development and Psychometric Evaluation of Healthcare Access Measures among Women with Ovarian Cancer.Cancers · 2022Article
- High Financial Hardship among Patients with Advanced Ovarian Cancer.Journal of social work in end-of-life & palliative careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo evaluate financial toxicity and assess its risk factors among patients with gynecologic cancers.
methodsThis is a cross sectional study that included 2 survey tools, as well as patient demographics, disease characteristics, and treatment regimen. Financial toxicity is measured by validated Comprehensive Score for Financial Toxicity (COST) tool. Participants were also asked to complete a 55-question-survey on attitudes and perspectives surrounding cost of care. Descriptive statistics was used to report patient demographics. Spearman's rank correlation was calculated to assess the relation between financial toxicity and patient/disease related variables. Graphpad Prism Software Version 8.0 was used for analyses.
resultsA total of 50 patients with various gynecologic malignancies were enrolled. Median COST score was 20.5 (range, 1-33). Sixty-five percent of the patients reported being in debt due to their cancer care and 4% filed bankruptcy. Correlation analysis showed that COST score was correlated with age (r=-0.3, p=0.028), malignancy type (r=0.3, p=0.039) and income (r=0.3, p=0.047). Ovarian cancer patients had significantly less financial toxicity (median COST score=23) when compared to patients with other gynecologic malignancies (median COST score=17, p=0.043). When scores were dichotomized into low (score ≥22) and high toxicity (score <22), 58% (29/50) of the patients were noted to have high financial toxicity. Enrollment to a clinical trial did not significantly alleviate financial burden.
conclusionFinancial toxicity is a significant burden even among highly insured gynecologic oncology patients. Age, malignancy type and income were correlated with high financial burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.